Email a Friende-mail
Print this Pageprint

Press Release

<p>GEORGIA REPRODUCTIVE SPECIALISTS CELEBRATES WITH ITS PATIENT NAMED AS WINNER OF FERRING&#8217;S <i>MY LITTLE MIRACLE</i> ESSAY CONTEST</p>
<p><strong>Ferring Presents $1,000 to Local Honorable Mention Winner</strong> </p> <table class="newsroom"> <tr> <td valign="top" width="60"><p><b>Contact:</b></p></td> <td width="20" valign="top"></td> <td width="258"><p>Kelly Laban<br> Kovak-Likly Communications<br> (203)762-8833 x15 or KLaban@KLCpr.com</p></td> </tr> </table> <p>Jeff Horne, reproductive and endocrine specialist, Ferring Pharmaceuticals, presents Kristi Pelot, honorable mention winner of its <i><b>My Little Miracle</b></i><b> Essay Contest</b>, with a $1,000 prize for her children, Max and Jackson, born with the help of Repronex&trade; (menotropins for injection, USP) - one of the Company&rsquo;s fertility treatments. </p> <p>Pictured from left to right: Jeff Horne, Ferring Pharmaceuticals, Kristi Pelot holding Max, and Eric Scott Sills, M.D., holding Jackson. </p> <p>ATLANTA &ndash; November 23, 2004 &ndash; Georgia Reproductive Specialists (GRS) announced today that its patient, Kristi Pelot, received a $1,000 honorable mention prize from Ferring Pharmaceuticals for her entry in the Company&rsquo;s <i>My Little Miracle </i>Essay Contest. Kristi&rsquo;s entry, <i>Two Heartbeats</i>, chronicled the path to her sons&rsquo; births. The prize money will be deposited into an education fund for Max and Jackson, her twenty-two-month-old sons born with the help of Repronex&trade; (menotropins for injection, USP) &ndash; one of Ferring&rsquo;s fertility treatments. The presentation was made on November 22nd at GRS&rsquo;s office in Atlanta. </p> <p>&#8220;I am so thrilled to have been chosen as a winner in the <i>My Little Miracle</i> Essay Contest,&#8221; said Kristi Pelot. &#8220;We are so pleased that our twin boys have a good start to their educational futures! Thank you, Ferring Pharmaceuticals, for making our dreams of parenthood a reality!&#8221; </p> <p>&#8220;Our entire team was elated to hear of yet another success story with Repronex&trade;,&#8221; added Eric Scott Sills, M.D., GRS. &#8220;The fact that Ferring supports this type of educational fund for the babies conceived with such therapy is commendable.&#8221; </p> <p>The <i>My Little Miracle</i> Essay Contest celebrated the births of children made possible through Ferring&rsquo;s fertility treatments, Bravelle&trade; (urofollitropin for injection, purified) and Repronex&trade; (menotropins for injection, USP). Ferring awarded $25,000 in education funds to 12 winners from around the country. </p> <p>&#8220;Ferring is delighted to offer this program to help fertility patients contribute to their children&rsquo;s future,&#8221; added Jeff Horne, reproductive and endocrine specialist, Ferring Pharmaceuticals. &#8220;Ferring is committed to providing patients with safe, effective and affordable fertility treatments. The <i>My Little Miracle</i> Essay Contest is an extension of Ferring&rsquo;s support of its patients.&#8221; </p> <p><strong>About the Pelots</strong> </p> <p>The Pelots unsuccessfully tried to conceive for three years and endured two early miscarriages before they sought treatment with a fertility specialist. The couple consulted Dr. Sills and began treatment. After one year of various treatment protocols, and in consultation with both Dr. Sills and another center physician, Mark Perloe, M.D., Kristi was prescribed a new treatment protocol with Repronex&trade;. In her essay, Kristi, speaks of their experience: </p> <blockquote> <i>&lsquo;I see one heartbeat &#8230; and &hellip; two heartbeats!&rsquo; said our doctor. &lsquo;I thought one of the eggs had no yolk in it!&rsquo; I said. &hellip; My husband and I looked at each other incredulously. We were not only pregnant, we were pregnant with twins! A week before, an ultrasound had confirmed our home pregnancy test. One of the eggs had looked healthy, while the other did not. &hellip; On the way home from our doctor&rsquo;s office, I stopped and bought a book on twins. We dubbed &lsquo;Baby B&rsquo; the &lsquo;Come-Back Kid,&rsquo; and he&rsquo;s been determined ever since! &hellip; Our boys have completely changed our lives, and my husband and I are very proud of every little milestone they reach. &hellip; we know [that] we are truly blessed and very thankful for two healthy boys.</i> </blockquote> <p><strong>About Bravelle&trade; and Repronex&trade;</strong><br/> Bravelle&trade; (urofollitropin for injection, purified), a highly purified human-derived follicle-stimulating hormone (hFSH) for infertility treatment, contains 75 IU of FSH and up to two percent LH activity. Bravelle&trade;, administered SC or IM in conjunction with hCG, is indicated for ovulation induction following pituitary suppression. Bravelle&trade;, administered SC in conjunction with hCG, is also indicated for multiple follicular development during ART cycles in patients who have previously received pituitary suppression. </p> <p>Repronex&trade; (menotropins for injection, USP) is the only human menopausal gonadotropin (hMG) on the market in the U.S. and is approved for both subcutaneous and intramuscular administration. </p> <p>Bravelle&trade; (urofollitropin for injection, purified) and Repronex&trade;, like all gonadotropins, are potent substances capable of causing mild to severe adverse reactions, including ovarian hyperstimulation syndrome (OHSS) (incidence of 6.0% and 3.5%, respectively), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. </p> <p>Both treatments are marketed by Ferring Pharmaceuticals Inc., a world leader in naturally occurring protein hormones. Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe these medications. Like other products for ovarian stimulation, treatment with <br>Repronex&trade; and/ or Bravelle&trade; may result in multiple gestations. </p> <p><strong>About Ferring Pharmaceuticals</strong> </p> <p>Ferring Pharmaceuticals, part of the Ferring Group, a privately owned, international pharmaceutical company, markets Bravelle&trade;, Repronex&trade; and Novarel&trade; (chorionic gonadotropin for injection, USP) in the U.S. to infertility specialists and their patients. The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology and infertility. For more information, call 888-337-7464 or visit <a href="http://www.ferringusa.com" target="_blank">www.ferringusa.com</a> or <a href="http://www.ferringfertility.com" target="_blank">www.ferringfertility.com</a>. </p> <p><strong>About Georgia Reproductive Specialists</strong><br/> Georgia Reproductive Specialists (GRS) leads the region in reproductive research and applies medical science&rsquo;s most advanced fertility technologies to provide the highest standards of patient-centered, reproductive healthcare. The staff at GRS, including infertility laboratory pioneer Michael Tucker, Ph.D., is focused on providing individualized, innovative solutions for reproductive challenges and infertility, specializing in <i>in vitro</i> fertilization, intracytoplasmic sperm injection and other assisted reproductive technologies. Fellowship-trained reproductive endocrinologists Dr. Susan C. Conway, Dr. Carolyn Kaplan, Dr. Mark Perloe and Dr. Eric Scott Sills, are experts in female and male disorders including polycystic ovary syndrome (PCOS), repeated pregnancy loss, menstrual disorders and azoospermia. GRS has three offices, Atlanta, Alpharetta and Decatur, to conveniently serve patients across Metro Atlanta. For more information about GRS, visit <a href="http://www.ivf.com" target="_blank">www.ivf.com</a>. </p> <p># # #<br/> <i>For full prescribing information for Bravelle&trade; and/ or Repronex&trade;, please contact Kelly Laban.</i> </p>

EUFLEXXA (1% sodium hyaluronate) is used to relieve knee pain due to osteoarthritis. It is used in people who do not get enough relief from simple pain medications such as acetaminophen or from exercise and physical therapy.

Important Safety Information
You should not receive this product if you have had any previous allergic reaction to EUFLEXXA or hyaluronan products. You should not have an injection into the knee if you have a knee joint infection or if you have skin disease or infection around the injection site.

EUFLEXXA is only for injection into the knee performed by a qualified doctor. After you receive this injection you may need to avoid activities such as jogging, tennis, heavy lifting, or standing on your feet for a long time (more than one hour). The safety and effectiveness of repeat treatment cycles of EUFLEXXA have not been established. The safety and effectiveness of EUFLEXXA have not been shown in people under 18 years of age.

Side effects sometimes seen when EUFLEXXA is injected into the knee joint were pain, swelling, skin irritation, and tenderness and these were generally mild and did not last long.

Please see Full Prescribing Information.

Please see Important Information for Patients.

Patient Treatment Information

PLEASE CONSULT WITH YOUR DOCTOR, OR OTHER QUALIFIED HEALTH CARE PROFESSIONAL BEFORE USING ANY PRODUCT DISCUSSED WITHIN THIS WEB SITE.

This website is intended only for US residents.

Euflexxa® is a registered trademark of Ferring Pharmaceuticals Inc.